Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Pedestrians walk past Pfizer world headquarters in New York on Nov. 9, 2020.

Bebeto Matthews/The Associated Press

Professor Jillian Kohler is the director of the WHO Collaborating Centre for Governance, Transparency and Accountability in the Pharmaceutical Sector and professor at University of Toronto’s Leslie Dan Faculty of Pharmacy. Jonathan Cushing is head of the Transparency International Health Initiative.

In the wake of the encouraging news about COVID-19 vaccine trials from Pfizer/BioNTech, Moderna and AstraZeneca, global attention is on pharmaceutical companies like never before. But in the understandable excitement, the companies in the spotlight risk overlooking a major opportunity: the chance to prioritize transparency and global health over profits, and build their credibility.

This will require a shift in how the industry operates, with increased focus on transparency and accountability in every step of the research and development process. The jury is still out on how far they are willing to go.

Story continues below advertisement

These four companies have shown an effort to increase transparency and accountability in their vaccine development efforts. Along with other pharmaceutical companies, they have pledged to “stand with science” and ensure that their vaccines undergo the accepted regulatory and safety standards before applying for approval or marketing authorization. In addition, Pfizer and BioNTech took a step further and joined Moderna by publishing their clinical trial protocol earlier than expected.

Historically, Pfizer has a 100 per cent clinical trial disclosure rate, meaning the results of its clinical trials have been published within 12 months of completion as per legal directives in the United States and the European Union. However BioNTech’s clinical transparency track record, albeit small, is not as strong, with the results from five out of its six clinical trials missing (four of which are overdue). Moderna has a similarly poor track record, with the results from all four of its completed clinical trials being overdue.

Furthermore, the four companies have faced legal action for patent infringement in relation to their respective COVID-19 vaccines. This adds to a growing number of lawsuits against Pfizer, which already has been subject to the largest pharmaceutical settlements in history in 2009, requiring it to pay US$2.3-billion for illegally promoting a range of its products, including Bextra, an anti-inflammatory drug the company marketed for certain usages and doses after it had been officially denied permission to do so by the FDA. Additionally, the U.S. Department of Defense launched an investigation into Moderna in September after it came to light that the company had failed to disclose federal funding in patent applications as required under U.S. law.

For both Pfizer/BioNTech and Moderna, the early vaccine data has been reported by press releases, an approach met by criticism, including by the editor-in-chief of the Lancet. This practice – as opposed to publishing the full data in a peer-reviewed medical journal – has been described by Dr. Peter Hotez of Baylor College of Medicine as “writing for their investors. … It’s being done in a way that’s oblivious to its public health impact and needs to stop.” Unsurprisingly, the positive news on the vaccine led to a nearly 15-per-cent increase in the price of Pfizer’s share and coincided with the CEO’s previously planned sale of 62 per cent of his stock (amounting to US$5.6-million). This move will only serve to undermine public trust and to buoy anti-vaxxers’ narratives.

Now more than ever, pharmaceutical companies need to uphold standards of social responsibility. For certain, it is challenging to mandate transparency from them while critical information can be shielded under the term “commercially sensitive information.” Still, billions of dollars in public funds have supported both the Pfizer/BioNTech and Moderna vaccine, either as research and development funding or as early investments. In the case of Moderna, bringing its vaccine to licence will have been entirely supported by public funds. Consequently, shareholders are not the only ones to whom pharmaceutical companies are accountable; the general public are also key investors.

Of note, 82 per cent of the global supply of the Pfizer/BioNTech vaccine and 78 per cent of the Moderna vaccine has already been bought by high-income countries through confidential bilateral agreements. These agreements undercut multilateral efforts such as COVAX, a global pooled procurement initiative established to guarantee a more equitable global distribution by ensuring vaccine doses for 20 per cent of participatory countries’ population. While AstraZeneca has joined COVAX, the three other companies have not, and have yet to announce how, or even if, they will take measures to ensure global equitable access to their vaccines.

To quote the CEO of Pfizer, Albert Bourla: “If you get it right, you can save the world. And if you don’t get it right, you will not.” But getting it right means much more than developing an effective vaccine – it demands transparency and accountability every step of the way, and a commitment to global equity in terms of deployment.

Story continues below advertisement

This is a watershed moment for the pharmaceutical industry as a whole. Let’s hope it embraces this opportunity and makes history for the right reasons.

Keep your Opinions sharp and informed. Get the Opinion newsletter. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies